Sarcopenic obesity and body composition phenotypes in older adults with chronic kidney disease: associations with estimated mortality risk Authors: Valer Donca, Ina Kacso, Lucretia Avram, Dana Crisan, Ariana Condor, Cosmina Bondor, Crina Rusu, Alina Potra, Dacian Tirinescu, Maria Ticala, Yuriy Maslyennikov, Alexandra Urs, Diana Moldovan Published: 2026 ABSTRACT Alterations in body composition are highly prevalent in older adults with chronic kidney disease (CKD) and may contribute to adverse health outcomes. In particular, the coexistence of sarcopenia and obesity—referred to as sarcopenic obesity—has emerged as a potentially high-risk nutritional phenotype. However, it remains unclear whether sarcopenia and obesity exert synergistic or merely additive effects on estimated geriatric risk in older adults with CKD. This cross-sectional study included 222 older adults (aged ≥ 70 years) with CKD (defined as estimated glomerular filtration rate [eGFR] < 60 mL/min/1.73 m2 and/or albuminuria ≥ 30 mg/g) who underwent comprehensive geriatric assessment and multimodal body composition evaluation. Sarcopenia was defined according to EWGSOP2 criteria using muscle strength and muscle mass assessed by bioelectrical impedance analysis and computed tomography. Obesity was defined as body mass index ≥ 30 kg/m2. Participants were classified into four body composition phenotypes: no sarcopenia/no obesity, obesity only, sarcopenia only, and sarcopenic obesity. Estimated 10-year mortality and disability risks were calculated using validated geriatric risk indices. Outcomes represent estimated risk scores rather than observed clinical events. Sarcopenia-related phenotypes were associated with higher estimated mortality risk (p < 0.001) and disability risk (p = 0.046). In multivariable analyses, lower eGFR, lower serum albumin, sarcopenia, and obesity were each independently associated with higher estimated mortality risk, whereas the interaction between sarcopenia and obesity was not significant, suggesting additive rather than synergistic effects. For disability risk, serum albumin was the only independent predictor; sarcopenia was not independently associated with estimated disability risk in the adjusted model. In this cross-sectional study of older adults with CKD, sarcopenia and obesity were independently associated with higher estimated mortality risk scores, with sarcopenia showing a stronger association. These exploratory findings support further evaluation of muscle-centered nutritional assessment beyond BMI in older adults with CKD, though prospective studies with observed clinical outcomes are needed to confirm these associations.Supplementary InformationThe online version contains supplementary material available at 10.1038/s41598-026-53294-w. Introduction Chronic kidney disease (CKD) is increasingly recognized as a condition characterized not only by progressive loss of kidney function but also by profound alterations in body composition, including muscle wasting and changes in adiposity, particularly in older adults. Aging and CKD share several pathophysiological mechanisms, including chronic inflammation, hormonal dysregulation, metabolic disturbances, and progressive loss of skeletal muscle mass and function. These processes contribute to significant changes in nutritional status and body composition, which may influence functional decline, frailty, and adverse outcomes1,2. Alterations in body composition are increasingly recognized as key determinants of health outcomes in aging populations. In particular, the progressive loss of skeletal muscle mass and strength, known as sarcopenia, has emerged as an important clinical condition associated with impaired mobility, reduced quality of life, and increased mortality. According to the revised European Working Group on Sarcopenia in Older People (EWGSOP2) consensus, sarcopenia is defined as a muscle disease characterized primarily by low muscle strength accompanied by reduced muscle quantity or quality3. Sarcopenia is now widely recognized as a central geriatric syndrome associated with functional decline and increased vulnerability in older adults4,5. Sarcopenia is a major complication of CKD also and has been associated with disability and mortality6,7. Recent studies have also highlighted the close relationship between sarcopenia, frailty, and functional decline in individuals with CKD8. In patients with CKD, several mechanisms contribute to the development of muscle loss, including chronic inflammation, metabolic acidosis, insulin resistance, hormonal disturbances, and reduced physical activity9,10. These mechanisms contribute to progressive muscle loss and reduced physical performance11,12, and sarcopenia is highly prevalent across CKD stages, with documented associations with hospitalization, and increased morbidity and mortality13. Emerging evidence also suggests a bidirectional relationship between CKD and sarcopenia in aging populations14,15. Importantly, nutritional factors—including malnutrition and protein-energy wasting—further contribute to muscle loss and are closely interrelated with sarcopenia risk in older adults with CKD16,17. Recent evidence suggests that malnutrition and sarcopenia risk frequently coexist, particularly in vulnerable populations, underscoring the importance of comprehensive nutritional assessment beyond isolated markers such as serum albumin18. At the same time, obesity is also common among individuals with CKD, particularly in older populations. Traditionally, obesity has been considered a risk factor for metabolic complications, cardiovascular disease, and progression of kidney dysfunction. Beyond its traditional role as a risk factor for metabolic complications and cardiovascular disease, obesity and nutrition in CKD are associated with specific pathophysiological consequences, including adipose tissue dysfunction, visceral fat-induced chronic inflammation, dysregulated adipokine signaling, and insulin resistance18,19. These metabolic disturbances may interact with CKD-related factors to amplify cardiovascular risk and functional decline20. However, the relationship between adiposity and outcomes in CKD appears complex. Several epidemiological studies have described an “obesity paradox,” whereby higher body mass index (BMI) is associated with improved survival in certain CKD populations, particularly among older or frail individuals1,2. These observations highlight the limitations of BMI as a marker of nutritional status and body composition in patients with chronic disease. Because BMI does not distinguish between fat mass and lean body mass, approaches that integrate multiple body composition components may provide a more comprehensive assessment of nutritional and functional status. Imaging-based techniques such as ultrasound and computed tomography have increasingly been used to characterize muscle quantity and quality in CKD populations21. In this context, increasing attention has been directed toward the coexistence of reduced muscle mass and excess adiposity, a condition commonly referred to as sarcopenic obesity. Sarcopenic obesity represents a complex body composition phenotype that combines the metabolic consequences of adiposity with the functional impact of muscle impairment22,23. In patients with CKD, the interaction between aging, kidney dysfunction, and body composition alterations may be particularly relevant. Recent studies in aging populations have suggested that sarcopenic obesity may be associated with increased risk of functional decline, disability, and mortality15. However, the independent contribution of this phenotype to adverse outcomes remains debated. In CKD specifically, some investigations indicate that the coexistence of sarcopenia and obesity confers particularly high risk, whereas others suggest that the association may be largely driven by the sarcopenic component rather than adiposity itself24. It remains unclear whether sarcopenia and obesity exert a synergistic (interactive) effect on mortality and disability risk in CKD, or whether the risk is merely additive and primarily attributable to the sarcopenic component. Despite increasing interest in sarcopenia and sarcopenic obesity, relatively few studies have investigated body composition phenotypes in older adults with CKD using integrated assessments of muscle strength, muscle mass, and adiposity. Most studies have focused on individual body composition components rather than phenotype-based classifications that may better reflect the combined effects of muscle impairment and adiposity. Furthermore, long-term clinical outcomes are often difficult to evaluate in cross-sectional cohorts of older patients. In such contexts, validated geriatric risk indices estimating long-term mortality and disability risk may provide useful insights into vulnerability and prognosis. Therefore, the aim of this study was to investigate body composition phenotypes defined by sarcopenia and obesity in older adults with CKD and to evaluate their association with estimated geriatric risk, assessed using validated mortality and disability risk indices, rather than observed clinical outcomes. Materials and methods Study design and population This cross-sectional analysis was conducted within a cohort of older adults who underwent comprehensive geriatric assessment. The study was derived from a prospectively maintained clinical database including individuals aged ≥ 70 years evaluated between 2020 and 2025. Participants were consecutively included in the geriatric assessment program and; of these, 670 of them met criteria for chronic kidney disease (CKD), defined as an estimated glomerular filtration rate (eGFR) < 60 mL/min/1.73 m2 and/or albuminuria ≥ 30 mg/g. Participants with complete data on body composition, muscle strength, and laboratory parameters were included in the final analysis and those with incomplete body composition or functional assessment data were excluded. The main reasons for exclusion were: computed tomography imaging not clinically indicated or not available, incomplete bioelectrical impedance analysis measurements, and missing handgrip strength data. A participant flow diagram is provided in Supplementary Fig. S1. The final study cohort consisted of 222 participants. Body composition assessment Body composition was evaluated using a multimodal approach integrating bioelectrical impedance analysis (BIA) and computed tomography (CT). Bioelectrical impedance analysis. BIA was performed using a multifrequency bioimpedance device (Visbody S30 Bioelectrical Impedance Body Composition Analyser Scanner, Xi’an, China), under standardized conditions according to established methodological recommendations25. Appendicular skeletal muscle mass index (ASMI) was calculated as appendicular skeletal muscle mass divided by height squared and expressed as kg/m2. Low muscle mass by BIA was defined as ASMI < 7.0 kg/m2 in men and < 5.5 kg/m2 in women, according to EWGSOP2 cutoffs3. Computed tomography. Muscle mass was also assessed using CT-derived skeletal muscle cross-sectional area measured at the level of the L3 vertebra. CT images were analyzed using semi-automated segmentation to quantify total skeletal muscle area (including psoas, paraspinal, and abdominal wall muscles) using previously described body composition imaging approaches26,27. Low muscle mass by CT was defined using sex-specific cutoffs based on published reference values (skeletal muscle index < 52.4 cm2/m2 in men and < 38.5 cm2/m2 in women). The combined use of BIA and CT-derived muscle measurements allowed a more robust characterization of skeletal muscle status compared with studies relying on a single modality. Sarcopenia definition. Sarcopenia was defined according to the criteria proposed by the European Working Group on Sarcopenia in Older People (EWGSOP2)3, based on reduced muscle strength combined with low muscle mass assessed by BIA and/or CT. Low muscle mass was defined as meeting the criterion on either BIA or CT (ASMI below the EWGSOP2 sex-specific cutoff by BIA, or skeletal muscle index below the sex-specific cutoff by CT, was sufficient in combination with low handgrip strength for the diagnosis of sarcopenia). Adiposity assessment and obesity definition. Adiposity was assessed using body mass index (BMI), waist circumference, and visceral fat estimates derived from BIA. Obesity was defined as BMI ≥ 30 kg/m2. This threshold was chosen for consistency with the existing sarcopenic obesity literature and the ESPEN/EASO consensus statement18. Although BMI does not distinguish between fat mass and lean mass and may not accurately reflect adiposity in older CKD populations, it remains the most widely used and comparable definition across studies. Waist circumference and BIA-derived visceral fat estimates were collected and are reported descriptively but were not used for the primary phenotype classification to maintain comparability. The potential for misclassification using BMI-based obesity definition is acknowledged as a limitation. Participants were classified into four body composition phenotypes: no sarcopenia/no obesity; obesity only; sarcopenia only; sarcopenic obesity. Functional and clinical assessment All participants underwent comprehensive geriatric assessment. Muscle strength was measured using handgrip strength with a calibrated dynamometer (model MVS-12-0241). Handgrip strength < 27 kg in men and < 16 kg in women was considered low muscle strength according to EWGSOP2 criteria3. Physical performance was evaluated using the Short Physical Performance Battery (SPPB). Functional status was assessed using the Activities of Daily Living (ADL) disability score, which counts the number of impaired activities (range 0–23; higher scores indicate greater functional impairment). Overall performance status was evaluated using the Eastern Cooperative Oncology Group (ECOG) scale. Laboratory parameters included serum creatinine, hemoglobin, albumin, C-reactive protein, and urinary albumin-to-creatinine ratio (UACR). Kidney function was estimated using the CKD-EPI 2021 creatinine equation. Outcomes Estimated 10-year mortality risk and 10-year disability risk were calculated using validated prognostic indices developed by Lee et al.28. The mortality index integrates age, sex, BMI, comorbid conditions (including diabetes, cancer, lung disease, and heart failure), functional limitations, and self-rated health to estimate 10-year mortality risk. The disability index incorporates age, self-rated health, hospitalization history, cognitive function, BMI, and functional status to estimate the probability of developing ADL disability. These indices generate continuous numerical risk scores ranging from 0 to 1, representing estimated probabilities of the respective outcomes. It should be noted that some components of these indices (e.g., age, BMI, functional status) may overlap conceptually with the exposure variables and covariates examined in this study. This potential circularity is acknowledged as a limitation. Importantly, these outcomes represent estimated risk scores derived from validated algorithms, not observed clinical events. Statistical analysis Continuous variables are presented as median (interquartile range), and categorical variables as number (percentage). Differences between body composition phenotypes were assessed using the Kruskal–Wallis test for continuous variables and the chi-square test for categorical variables. Multivariable linear regression analyses were performed to identify factors associated with estimated mortality risk and disability risk. Because the outcomes represented continuous estimated risk scores rather than observed time-to-event data, survival regression models (e.g., Cox proportional hazards, Weilbull) were not applicable, as there is no censoring, no follow-up time, and no observed events. Linear regression was chosen because the estimated risk scores were treated as continuous summary indices of vulnerability. Model diagnostics were performed. Variance inflation factors (VIF) for all predictors were below 2.5, indicating no substantial multicollinearity. Residual distributions were inspected visually and showed no major departures from normality. We acknowledge that the bounded nature of the outcome variables (0–1) represents a limitation of the linear regression approach. Variables included in the models were kidney function (eGFR), albuminuria (UACR), inflammatory markers (C-reactive protein), nutritional status (serum albumin), sarcopenia, obesity, and the interaction between sarcopenia and obesity. Data on CKD etiology, dialysis status and vintage, physical activity levels, detailed comorbidity burden, and comprehensive medication use were not systematically available for all participants and could not be included in the multivariable models. This represents a potential source of residual confounding and is discussed in the limitations. Physical performance measures (SPPB, gait speed) were collected but were not included as covariates in the regression models to avoid circularity, as the prognostic indices already incorporate functional variables. Statistical significance was defined as p < 0.05. All analyses were performed using Microsoft Excel and SPSS 25.0. Results Study population Of the 670 older adults meeting CKD criteria, 222 had complete data and were included in the final analysis (Supplementary Fig. S1). Participants were classified into four body composition phenotypes based on the presence of sarcopenia and obesity: no sarcopenia and no obesity (n = 59, 26.6%), obesity only (n = 62, 27.9%), sarcopenia only (n = 74, 33.3%), and sarcopenic obesity (n = 27, 12.2%). Baseline characteristics according to body composition phenotype The baseline characteristics of the study population according to body composition phenotype are presented in Table 1. Table 1Baseline characteristics of the study population according to body composition phenotype.VariableTotal (n = 222)No sarcopenia/no obesity (n = 59)Obesity only (n = 62)Sarcopenia only (n = 74)Sarcopenic obesity (n = 27)p valueAge, years82.15 (77.57–85.88)81.01 (76.13–84.55)80.4 (76–84.99)83.87 (80.22–87.85)85.22 (79.18–88.02) < 0.001 Male sex, n (%)62 (27.9%)15 (25.4%)11 (17.7%)28 (37.8%)8 (29.6%)0.071BMI, kg/m228.57 (23.74–32.42)26.93 (23.61–28.87)33.05 (31.25–37.37)23.12 (20.09–26.10)32.58 (30.93–34.88) < 0.001 Waist circumference, cm101 (91–112)96 (89.5–102.4)111 (104.5–120)90 (82–98)110 (103.5–114.75) < 0.001 Visceral fat (BIA)11 (6–14)11 (8–12)15 (13–17)7 (4.5–10)13 (9.5–16.5) < 0.001 Handgrip strength, kg16 (12–21)19 (15–26)18 (15–22)14 (10–18)15 (8–19) < 0.001 ASMI, kg/m26.94 (6.37–7.73)7.42 (6.59–7.73)7.81 (7.24–8.45)6.03 (5.63–6.51)6.82 (6.48–6.89) < 0.001 Skeletal muscle area (CT), cm2107.54 (95.51–123.15)110.2 (103.28–120.05)122.16 (111.05–139.17)94.12 (85.36–111.26)99.18 (93.35–118.07) < 0.001 SPPB score4 (1–7)7 (4–8)6 (3–9)5 (2–7)3 (1–6) 0.003 eGFR (CKD-EPI), mL/min/1.73 m251.16 (37.31–70.41)52.51 (42.37–66.27)51.77 (40.12–59.17)52.98 (39.19–69.96)52.05 (36.66–59.14)0.794UACR, mg/g42.74 (16.37–108.37)49.92 (13.94–113.49)40.35 (13.93–98.6)59.48 (18.27–152.09)31.31 (10.84–105.62)0.102Hemoglobin, g/dL12.5 (11.1–13.5)12 (10.95–13.2)12.9 (11.4–13.7)12.5 (11–13.4)12.5 (10.3–13.55)0.518Albumin, g/dL4.15 (3.8–4.4)4.2 (3.9–4.6)4.3 (4–4.5)4.1 (3.8–4.5)4.1 (3.8–4.3)0.082C-reactive protein, mg/L0.56 (0.19–2.15)0.43 (0.12–1.39)0.40 (0.18–1.36)0.59 (0.14–2.91)0.59 (0.27–1.73)0.523ADL score5 (0–16)2 (0–8.5)2 (0–9)5 (1–15.5)6 (2–15) 0.014 ECOG performance status2 (1–3)1 (1–2.5)1 (1–2)2 (1–3)2 (1–3) 0.044 Estimated 10-year mortality risk0.91 (0.69–0.99)0.83 (0.60–0.97)0.83 (0.56–0.97)0.97 (0.91–1.00)0.93 (0.85–0.99) < 0.001 Estimated 10-year ADL disability risk0.71 (0.56–0.85)0.64 (0.52–0.79)0.66 (0.53–0.82)0.75 (0.61–0.85)0.71 (0.63–0.89) 0.046 Values are presented as median (interquartile range) or number (percentage). Comparisons between groups were performed using Kruskal–Wallis tests for continuous variables and chi-square tests for categorical variables. Sarcopenia was defined according to EWGSOP2 criteria using muscle strength and muscle mass assessed by BIA and/or CT. Obesity was defined as BMI ≥ 30 kg/m2. ECOG Eastern cooperative oncology group: "Bold p values indicate statistical significance (p < 0.05).BMI Body mass index, ASMI Appendicular skeletal muscle mass index; SPPB Short physical performance battery; eGFR Estimated glomerular filtration rate; UACR Urinary albumin-to-creatinine ratio; ADL Activities of daily living; ECOG Eastern cooperative oncology group. Table 1Baseline characteristics of the study population according to body composition phenotype.VariableTotal (n = 222)No sarcopenia/no obesity (n = 59)Obesity only (n = 62)Sarcopenia only (n = 74)Sarcopenic obesity (n = 27)p valueAge, years82.15 (77.57–85.88)81.01 (76.13–84.55)80.4 (76–84.99)83.87 (80.22–87.85)85.22 (79.18–88.02) < 0.001 Male sex, n (%)62 (27.9%)15 (25.4%)11 (17.7%)28 (37.8%)8 (29.6%)0.071BMI, kg/m228.57 (23.74–32.42)26.93 (23.61–28.87)33.05 (31.25–37.37)23.12 (20.09–26.10)32.58 (30.93–34.88) < 0.001 Waist circumference, cm101 (91–112)96 (89.5–102.4)111 (104.5–120)90 (82–98)110 (103.5–114.75) < 0.001 Visceral fat (BIA)11 (6–14)11 (8–12)15 (13–17)7 (4.5–10)13 (9.5–16.5) < 0.001 Handgrip strength, kg16 (12–21)19 (15–26)18 (15–22)14 (10–18)15 (8–19) < 0.001 ASMI, kg/m26.94 (6.37–7.73)7.42 (6.59–7.73)7.81 (7.24–8.45)6.03 (5.63–6.51)6.82 (6.48–6.89) < 0.001 Skeletal muscle area (CT), cm2107.54 (95.51–123.15)110.2 (103.28–120.05)122.16 (111.05–139.17)94.12 (85.36–111.26)99.18 (93.35–118.07) < 0.001 SPPB score4 (1–7)7 (4–8)6 (3–9)5 (2–7)3 (1–6) 0.003 eGFR (CKD-EPI), mL/min/1.73 m251.16 (37.31–70.41)52.51 (42.37–66.27)51.77 (40.12–59.17)52.98 (39.19–69.96)52.05 (36.66–59.14)0.794UACR, mg/g42.74 (16.37–108.37)49.92 (13.94–113.49)40.35 (13.93–98.6)59.48 (18.27–152.09)31.31 (10.84–105.62)0.102Hemoglobin, g/dL12.5 (11.1–13.5)12 (10.95–13.2)12.9 (11.4–13.7)12.5 (11–13.4)12.5 (10.3–13.55)0.518Albumin, g/dL4.15 (3.8–4.4)4.2 (3.9–4.6)4.3 (4–4.5)4.1 (3.8–4.5)4.1 (3.8–4.3)0.082C-reactive protein, mg/L0.56 (0.19–2.15)0.43 (0.12–1.39)0.40 (0.18–1.36)0.59 (0.14–2.91)0.59 (0.27–1.73)0.523ADL score5 (0–16)2 (0–8.5)2 (0–9)5 (1–15.5)6 (2–15) 0.014 ECOG performance status2 (1–3)1 (1–2.5)1 (1–2)2 (1–3)2 (1–3) 0.044 Estimated 10-year mortality risk0.91 (0.69–0.99)0.83 (0.60–0.97)0.83 (0.56–0.97)0.97 (0.91–1.00)0.93 (0.85–0.99) < 0.001 Estimated 10-year ADL disability risk0.71 (0.56–0.85)0.64 (0.52–0.79)0.66 (0.53–0.82)0.75 (0.61–0.85)0.71 (0.63–0.89) 0.046 Values are presented as median (interquartile range) or number (percentage). Comparisons between groups were performed using Kruskal–Wallis tests for continuous variables and chi-square tests for categorical variables. Sarcopenia was defined according to EWGSOP2 criteria using muscle strength and muscle mass assessed by BIA and/or CT. Obesity was defined as BMI ≥ 30 kg/m2. ECOG Eastern cooperative oncology group: "Bold p values indicate statistical significance (p < 0.05).BMI Body mass index, ASMI Appendicular skeletal muscle mass index; SPPB Short physical performance battery; eGFR Estimated glomerular filtration rate; UACR Urinary albumin-to-creatinine ratio; ADL Activities of daily living; ECOG Eastern cooperative oncology group. Baseline characteristics of the study population according to body composition phenotype. Values are presented as median (interquartile range) or number (percentage). Comparisons between groups were performed using Kruskal–Wallis tests for continuous variables and chi-square tests for categorical variables. Sarcopenia was defined according to EWGSOP2 criteria using muscle strength and muscle mass assessed by BIA and/or CT. Obesity was defined as BMI ≥ 30 kg/m2. ECOG Eastern cooperative oncology group: "Bold p values indicate statistical significance (p < 0.05). BMI Body mass index, ASMI Appendicular skeletal muscle mass index; SPPB Short physical performance battery; eGFR Estimated glomerular filtration rate; UACR Urinary albumin-to-creatinine ratio; ADL Activities of daily living; ECOG Eastern cooperative oncology group. The median age of the study population was 82.15 years, with participants with sarcopenia and sarcopenic obesity being significantly older compared with the other groups (p < 0.001). The proportion of men did not differ significantly between phenotypes (p = 0.071). Anthropometric parameters differed markedly across body composition phenotypes. Participants with obesity and sarcopenic obesity had significantly higher BMI, waist circumference, and visceral fat levels compared with participants without obesity (all p < 0.001). Markers of muscle strength and muscle mass also differed significantly between groups, with participants with sarcopenia, including those with sarcopenic obesity showing significantly lower handgrip strength, ASMI, and CT-derived skeletal muscle area at L3 (all p < 0.001). Physical performance also varied across phenotypes. The Short Physical Performance Battery (SPPB) score was significantly lower among participants with sarcopenia and sarcopenic obesity (p = 0.003). Kidney function and most laboratory parameters, including eGFR, albuminuria, hemoglobin, serum albumin, and C-reactive protein, did not differ significantly between body composition phenotypes. Functional status differed between groups: participants with sarcopenia and sarcopenic obesity had higher ADL disability scores (indicating greater functional impairment) and worse ECOG performance status. Additional anthropometric, functional, and laboratory variables are presented in Supplementary Table S1. Participants with sarcopenic obesity were the oldest subgroup, whereas those with obesity only were younger on average. As expected, anthropometric parameters differed markedly across phenotypes, with significantly higher body mass index, waist circumference, skinfold thickness, triglycerides, and visceral fat estimates in groups with obesity. Functional performance measures showed a similar pattern, with higher chair stand test and lower gait speed scores and lower calf circumference observed in sarcopenic phenotypes. Estimated mortality and disability risk across phenotypes Estimated 10-year mortality risk differed significantly across body composition phenotypes (p < 0.001). Both sarcopenic phenotypes exhibited higher estimated mortality risk compared with non-sarcopenic groups: the sarcopenia-only group had the highest median estimated mortality risk (0.97), followed by the sarcopenic obesity group (0.93), compared with the no sarcopenia/no obesity group (0.83) and the obesity-only group (0.83). Estimated ADL disability risk also differed between groups (p = 0.046), with the highest values observed in participants with sarcopenia and sarcopenic obesity. The distribution of estimated mortality and disability risk across body composition phenotypes is illustrated in Fig. 1. Fig. 1Distribution of estimated mortality and disability risk across body composition phenotypes in older adults with chronic kidney disease. Boxplots represent the median, interquartile range, and outliers of the estimated 10-year mortality risk (A) and estimated 10-year ADL disability risk (B) according to body composition phenotype. Distribution of estimated mortality and disability risk across body composition phenotypes in older adults with chronic kidney disease. Boxplots represent the median, interquartile range, and outliers of the estimated 10-year mortality risk (A) and estimated 10-year ADL disability risk (B) according to body composition phenotype. Multivariable associations with estimated mortality risk Multivariable linear regression analysis was performed to identify factors associated with estimated 10-year mortality risk (Table 2). Table 2Multivariable linear regression analysis for estimated 10-year mortality risk.VariableBSE95% CIBetaFp valueeGFR (mL/min/1.73 m2)− 0.0010.001− 0.003 to − 0.00003− 0.1374.080 0.045 UACR (mg/g)0.000040.00006− 0.00008 to 0.00020.0410.3600.549C-reactive protein0.0030.005− 0.007 to 0.0130.0440.4120.522Serum albumin (g/dL)− 0.0750.037− 0.148 to − 0.002− 0.1404.131 0.044 Sarcopenia0.0890.0350.020 to 0.1580.1786.400 0.012 Obesity0.0680.0340.002 to 0.1350.1384.103 0.045 Sarcopenia × Obesity− 0.0620.062− 0.184 to 0.060− 0.0761.0040.318Model statistics: F(7, 214) = 5.116; p < 0.001; R2 = 0.197; Adjusted R2 = 0.158.B Unstandardized regression coefficient; SE Standard error; CI Confidence interval; Beta Standardized coefficient; eGFR Estimated glomerular filtration rate; UACR Urinary albumin-to-creatinine ratio; BMI = body mass index.Reference categories: no sarcopenia, no obesity. Sarcopenia was defined according to EWGSOP2 criteria (low handgrip strength combined with low muscle mass by BIA and/or CT). Obesity was defined as BMI ≥ 30 kg/m2. A positive B coefficient indicates that the variable is associated with higher estimated mortality risk. Bold p values indicate statistical significance (p < 0.05). The non-significant interaction term (Sarcopenia × Obesity) suggests additive rather than synergistic effects. Table 2Multivariable linear regression analysis for estimated 10-year mortality risk.VariableBSE95% CIBetaFp valueeGFR (mL/min/1.73 m2)− 0.0010.001− 0.003 to − 0.00003− 0.1374.080 0.045 UACR (mg/g)0.000040.00006− 0.00008 to 0.00020.0410.3600.549C-reactive protein0.0030.005− 0.007 to 0.0130.0440.4120.522Serum albumin (g/dL)− 0.0750.037− 0.148 to − 0.002− 0.1404.131 0.044 Sarcopenia0.0890.0350.020 to 0.1580.1786.400 0.012 Obesity0.0680.0340.002 to 0.1350.1384.103 0.045 Sarcopenia × Obesity− 0.0620.062− 0.184 to 0.060− 0.0761.0040.318Model statistics: F(7, 214) = 5.116; p < 0.001; R2 = 0.197; Adjusted R2 = 0.158.B Unstandardized regression coefficient; SE Standard error; CI Confidence interval; Beta Standardized coefficient; eGFR Estimated glomerular filtration rate; UACR Urinary albumin-to-creatinine ratio; BMI = body mass index.Reference categories: no sarcopenia, no obesity. Sarcopenia was defined according to EWGSOP2 criteria (low handgrip strength combined with low muscle mass by BIA and/or CT). Obesity was defined as BMI ≥ 30 kg/m2. A positive B coefficient indicates that the variable is associated with higher estimated mortality risk. Bold p values indicate statistical significance (p < 0.05). The non-significant interaction term (Sarcopenia × Obesity) suggests additive rather than synergistic effects. Multivariable linear regression analysis for estimated 10-year mortality risk. Model statistics: F(7, 214) = 5.116; p < 0.001; R2 = 0.197; Adjusted R2 = 0.158. B Unstandardized regression coefficient; SE Standard error; CI Confidence interval; Beta Standardized coefficient; eGFR Estimated glomerular filtration rate; UACR Urinary albumin-to-creatinine ratio; BMI = body mass index. Reference categories: no sarcopenia, no obesity. Sarcopenia was defined according to EWGSOP2 criteria (low handgrip strength combined with low muscle mass by BIA and/or CT). Obesity was defined as BMI ≥ 30 kg/m2. A positive B coefficient indicates that the variable is associated with higher estimated mortality risk. Bold p values indicate statistical significance (p < 0.05). The non-significant interaction term (Sarcopenia × Obesity) suggests additive rather than synergistic effects. After adjustment for kidney function, albuminuria, inflammatory markers, and nutritional status, lower eGFR (B = − 0.001, 95% CI − 0.003 to − 0.00003, p = 0.045), lower serum albumin (B = − 0.075, 95% CI − 0.148 to − 0.002, p = 0.044), presence of sarcopenia (B = 0.089, 95% CI 0.020 to 0.158, p = 0.012), and presence of obesity (B = 0.068, 95% CI 0.002 to 0.135, p = 0.045) were independently associated with higher estimated mortality risk. Sarcopenia showed a stronger independent association than obesity, as reflected by a higher standardized coefficient (β = 0.178 vs. 0.138) and a lower p-value. The interaction between sarcopenia and obesity was not statistically significant (B = − 0.062, 95% CI − 0.184 to 0.060, p = 0.318), suggesting that their effects on estimated mortality risk were additive rather than synergistic. Albuminuria and C-reactive protein were not significantly associated with estimated mortality risk. The overall model explained approximately 20% of the variance in estimated mortality risk (R2 = 0.197; adjusted R2 = 0.158; p < 0.001). Multivariable associations with estimated disability risk Multivariable linear regression analysis was also performed to evaluate factors associated with estimated 10-year risk of ADL disability (Table 3). Table 3Multivariable linear regression analysis for estimated 10-year ADL disability risk.VariableBSE95% CIBetaFp valueeGFR (mL/min/1.73 m2)− 0.0010.001− 0.002 to 0.001− 0.0831.4020.238UACR (mg/g)0.0000060.00006− 0.0001 to 0.00010.0070.0110.918C-reactive protein0.0060.005− 0.004 to 0.0160.0821.3720.243Serum albumin (g/dL)− 0.0840.038− 0.159 to − 0.008− 0.1554.827 0.030 Sarcopenia0.0440.036-0.028 to 0.1150.0861.4760.226Obesity0.0090.035-0.059 to 0.0780.0190.0720.788Sarcopenia × Obesity− 0.0100.063− 0.135 to 0.114− 0.0130.0270.871Model statistics: F model = 2.895; p = 0.007; R2 = 0.122; Adjusted R2 = 0.080. Notes. Multivariable linear regression models were adjusted for kidney function, albuminuria, inflammatory markers, and nutritional status. Sarcopenia was defined according to EWGSOP2 criteria, and obesity as BMI ≥ 30 kg/m2.B Unstandardized regression coefficient; SE Standard error; CI Confidence interval; Beta Standardized coefficient; eGFR Estimated glomerular filtration rate; UACR Urinary albumin-to-creatinine ratio; BMI Body mass index.Reference categories: no sarcopenia, no obesity. Sarcopenia was defined according to EWGSOP2 criteria. Obesity was defined as BMI ≥ 30 kg/m2. A negative B coefficient for serum albumin indicates that lower albumin is associated with higher estimated disability risk. Bold p values indicate statistical significance (p < 0.05). Sarcopenia, obesity, and their interaction were not significantly associated with estimated disability risk in this adjusted model. Table 3Multivariable linear regression analysis for estimated 10-year ADL disability risk.VariableBSE95% CIBetaFp valueeGFR (mL/min/1.73 m2)− 0.0010.001− 0.002 to 0.001− 0.0831.4020.238UACR (mg/g)0.0000060.00006− 0.0001 to 0.00010.0070.0110.918C-reactive protein0.0060.005− 0.004 to 0.0160.0821.3720.243Serum albumin (g/dL)− 0.0840.038− 0.159 to − 0.008− 0.1554.827 0.030 Sarcopenia0.0440.036-0.028 to 0.1150.0861.4760.226Obesity0.0090.035-0.059 to 0.0780.0190.0720.788Sarcopenia × Obesity− 0.0100.063− 0.135 to 0.114− 0.0130.0270.871Model statistics: F model = 2.895; p = 0.007; R2 = 0.122; Adjusted R2 = 0.080. Notes. Multivariable linear regression models were adjusted for kidney function, albuminuria, inflammatory markers, and nutritional status. Sarcopenia was defined according to EWGSOP2 criteria, and obesity as BMI ≥ 30 kg/m2.B Unstandardized regression coefficient; SE Standard error; CI Confidence interval; Beta Standardized coefficient; eGFR Estimated glomerular filtration rate; UACR Urinary albumin-to-creatinine ratio; BMI Body mass index.Reference categories: no sarcopenia, no obesity. Sarcopenia was defined according to EWGSOP2 criteria. Obesity was defined as BMI ≥ 30 kg/m2. A negative B coefficient for serum albumin indicates that lower albumin is associated with higher estimated disability risk. Bold p values indicate statistical significance (p < 0.05). Sarcopenia, obesity, and their interaction were not significantly associated with estimated disability risk in this adjusted model. Multivariable linear regression analysis for estimated 10-year ADL disability risk. Model statistics: F model = 2.895; p = 0.007; R2 = 0.122; Adjusted R2 = 0.080. Notes. Multivariable linear regression models were adjusted for kidney function, albuminuria, inflammatory markers, and nutritional status. Sarcopenia was defined according to EWGSOP2 criteria, and obesity as BMI ≥ 30 kg/m2. B Unstandardized regression coefficient; SE Standard error; CI Confidence interval; Beta Standardized coefficient; eGFR Estimated glomerular filtration rate; UACR Urinary albumin-to-creatinine ratio; BMI Body mass index. Reference categories: no sarcopenia, no obesity. Sarcopenia was defined according to EWGSOP2 criteria. Obesity was defined as BMI ≥ 30 kg/m2. A negative B coefficient for serum albumin indicates that lower albumin is associated with higher estimated disability risk. Bold p values indicate statistical significance (p < 0.05). Sarcopenia, obesity, and their interaction were not significantly associated with estimated disability risk in this adjusted model. In the adjusted model, serum albumin was the only variable independently associated with higher estimated disability risk (B = − 0.084, 95% CI − 0.159 to − 0.008, p = 0.030), indicating that lower serum albumin was associated with higher estimated disability risk. Kidney function, albuminuria, inflammatory markers, sarcopenia, obesity, and the interaction between sarcopenia and obesity were not significantly associated with estimated disability risk. The model explained approximately 12% of the variance in estimated disability risk (R2 = 0.122; adjusted R2 = 0.080; p = 0.007). Across multivariable analyses, both sarcopenia and obesity were independently associated with higher estimated mortality risk, with sarcopenia demonstrating a more robust independent association. For estimated disability risk, only serum albumin was a significant predictor. The interaction between sarcopenia and obesity was not significant in either model, suggesting additive rather than synergistic effects of these body composition components on estimated geriatric risk. Discussion Main findings In this study cross-sectional of older adults with CKD, we evaluated body composition phenotypes defined by the coexistence of sarcopenia and obesity and their association with estimated geriatric risk. Three main findings emerged. First, sarcopenia-related phenotypes were associated with significantly higher estimated mortality and disability risk in descriptive analyses. Second, in multivariable models, both sarcopenia and obesity were independently associated with higher estimated mortality risk, with sarcopenia showing a stronger independent association. Third, the interaction between sarcopenia and obesity was not significant, suggesting additive rather than synergistic effects on estimated mortality risk. These findings highlight the importance of muscle impairment in determining vulnerability among older adults with CKD, while also indicating that obesity independently contributes to estimated mortality risk. Sarcopenia is increasingly recognized as a major complication of CKD and has been associated with physical decline, reduced physical performance, and increased mortality risk13,29. Several mechanisms may contribute to muscle loss in CKD populations, including chronic inflammation, metabolic acidosis, hormonal alterations, and reduced physical activity12. Nutritional disturbances and metabolic alterations are common in CKD and may contribute to muscle wasting and vulnerability16,17. Recent evidence indicates that malnutrition and sarcopenia risk frequently coexist in older adults, underscoring the need for comprehensive nutritional assessment beyond individual markers18,30. It should be emphasized that the findings of this study are associative in nature and should be considered exploratory and hypothesis-generating. The cross-sectional design precludes causal inference, and unmeasured upstream factors—including physical inactivity, comorbidity burden, disease severity, CKD etiology, and medication use—may partly explain the observed associations between body composition phenotypes and estimated geriatric risk. Sarcopenia, obesity, and the concept of sarcopenic obesity The coexistence of reduced muscle mass and excess adiposity has received increasing attention in recent years because of its potential to combine the metabolic consequences of obesity with the functional impact of muscle impairment. Several studies in aging populations have suggested that sarcopenic obesity may be associated with increased risk of disability and mortality31. However, the independent contribution of sarcopenic obesity to adverse outcomes remains debated. In CKD specifically, some investigations indicate that the coexistence of sarcopenia and obesity confers particularly high risk, whereas others suggest that the association may be primarily driven by the sarcopenic component16,24. In our study, the non-significant interaction term indicates a lack of demonstrated synergistic effect between sarcopenia and obesity on estimated mortality risk, rather than evidence that adiposity is irrelevant. Indeed, both sarcopenia and obesity reached statistical significance as independent predictors in the mortality model, suggesting that their effects are additive. The small number of participants with sarcopenic obesity (n = 27) may have limited statistical power to detect interaction effects, and the non-significant interaction term may reflect type II error. Obesity and the obesity paradox in CKD An important finding of this study is that obesity was independently associated with higher estimated mortality risk in the multivariable model. This contrasts with the widely described obesity paradox in CKD, whereby higher BMI has been associated with improved survival in some populations1,2. Several explanations may account for this observation. First, the estimated risk indices used in this study capture different dimensions of vulnerability than observed survival outcomes; the prognostic index incorporates age, comorbidities, and functional status, and may assign higher risk to obese individuals through these pathways. Second, the concurrent assessment of muscle mass may have unmasked adiposity-related risk that BMI alone conceals—when sarcopenia is accounted for, the residual effect of adiposity may reflect metabolic and inflammatory burden rather than nutritional reserve. Third, the obesity paradox may not apply uniformly to all CKD subpopulations, and its protective effect may be attenuated in very old individuals with comprehensive geriatric assessment2. Body composition parameters, including fat mass and fat distribution, have been shown to be associated with cardiometabolic risk in CKD populations, suggesting that adiposity is not metabolically neutral even when not reaching statistical significance in some models19. Body composition phenotypes and nutritional assessment in CKD Our findings are consistent with the limitations of BMI as an isolated marker of nutritional status. Approaches integrating muscle strength, muscle mass, and adiposity assessment may provide a more accurate characterization of vulnerability and risk in older adults with CKD32,33. Nutritional factors and dietary patterns have been increasingly recognized as important determinants of muscle health and sarcopenia risk in aging populations31. Beyond traditional anthropometric measures, the evaluation of muscle strength, muscle mass, and functional performance may provide a more accurate characterization of disability and mortality risk in older adults with CKD32,33.The nutrition–sarcopenia axis is increasingly recognized as central in geriatric populations: malnutrition screening tools such as the Mini Nutritional Assessment (MNA) and the GLIM criteria provide more comprehensive nutritional risk stratification than BMI or albumin alone34,35. The absence of validated nutritional screening tools in this study is an important limitation that should be addressed in future research. Comparison with findings from other population contexts is informative. Studies in hospitalized older adults have demonstrated the coexistence of malnutrition and sarcopenia risk in vulnerable populations18, while investigations in hemodialysis patients have emphasized that body composition components interact with cardiometabolic pathways and that fat distribution influences outcomes even when not independently significant in adjusted models 19. These perspectives reinforce the importance of a comprehensive approach encompassing muscle, fat, and metabolism rather than focusing on muscle impairment alone. Estimated risk scores and clinical interpretability An important methodological consideration is that our study population had a median age above 80 years, meaning that the 10-year prediction horizon of the risk indices extends into very advanced ages (≥ 90 years), where mortality risk is inherently high due to aging alone. Furthermore, the outcomes represent estimated risk scores rather than observed clinical events, introducing an additional layer of abstraction. Taken together, these aspects limit the clinical interpretability of the reported associations and raise the possibility that the findings may partly reflect age-related baseline risk rather than body composition–specific effects. Accordingly, the findings are best interpreted as reflecting relative vulnerability across body composition phenotypes rather than absolute prognostic predictions. Strengths and limitations This study has several strengths. First, it was conducted in a well-characterized cohort of older adults with CKD who underwent comprehensive geriatric assessment. Second, sarcopenia was assessed using both functional and structural measures, including muscle strength, bioelectrical impedance analysis–derived ASMI, and CT-based muscle area, providing a robust characterization of body composition than studies relying on a single modality. Several limitations should be acknowledged. First, the cross-sectional design precludes causal inference; it is not possible to determine whether sarcopenia contributes to higher risk or simply reflects a population that is already more vulnerable. Second, the outcomes evaluated in this study represent estimated geriatric risk scores rather than observed clinical events, which limits clinical interpretability. Third, the relatively small number of participants with sarcopenic obesity may have limited the statistical power to detect interaction effects, and the non-significant interaction term may reflect type II error. Fourth, the exclusion of participants with incomplete body composition data introduces potential selection bias, as excluded individuals may have been more frail or more severely ill; however, exclusions were primarily driven by the unavailability of specific investigations rather than clinical characteristics. Fifth, obesity was defined using BMI alone, which does not distinguish between visceral and subcutaneous fat and may lead to misclassification; although waist circumference and BIA-derived visceral fat estimates were collected, these were not used for the primary phenotype classification. Sixth, no validated nutritional screening tool was used, and dietary intake data were not available; serum albumin, used as a nutritional marker, is sensitive to inflammation and other non-nutritional factors. Seventh, important potential confounders—including CKD etiology, dialysis status and vintage, physical activity levels, detailed comorbidity burden, and medication use—were not available for inclusion in the models, raising concerns about residual confounding. Eighth, some components of the prognostic indices may overlap conceptually with the exposure variables, introducing potential circularity; the linear regression approach for bounded outcome variables (0–1) is a simplification. Finally, the findings are based on a single-center European cohort of very old adults with CKD and may not be generalizable to other populations. Clinical implications The present findings have several potential clinical implications, though they should be interpreted with caution given the cross-sectional design and estimated nature of the outcomes. First, they support further evaluation of systematic muscle health assessment in older adults with CKD. Second, body composition phenotypes may provide more clinically relevant information than BMI-based classifications alone. Third, the results support the exploration of interventions targeting muscle health, including nutritional optimization and physical activity programs, as potential strategies to mitigate vulnerability in aging CKD populations34–36. Future prospective studies with observed clinical outcomes are needed to confirm these associations. Conclusions In this cross-sectional study of older adults with chronic kidney disease, body composition phenotypes were associated with differences in estimated geriatric risk scores. In descriptive analyses, sarcopenia-related phenotypes were characterized by higher estimated mortality and disability risk. In multivariable analyses, both sarcopenia and obesity were independently associated with higher estimated mortality risk scores, with sarcopenia showing a stronger independent association. The interaction between sarcopenia and obesity was not significant, suggesting additive rather than synergistic effects. For estimated disability risk, serum albumin was the only independent predictor; sarcopenia was not independently associated with estimated disability risk in the adjusted model. These exploratory findings, based on estimated risk scores rather than observed clinical outcomes, support further evaluation of muscle-centered nutritional assessment—including evaluation of muscle strength and muscle mass—in the clinical management of older adults with CKD. Prospective studies with observed clinical endpoints are needed to confirm these associations and to determine whether interventions targeting muscle health can improve outcomes in this population. Supplementary Information Below is the link to the electronic supplementary material. Supplementary Material 1 Supplementary Material 1 Supplementary Material 2 Supplementary Material 2